Julien Volet - Concepedia

Author

Julien Volet

Université de Reims Champagne-Ardenne

Also Known As

Caroline Couffon, J Volet, J. Volet, Julien Volet

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Université de Reims Champagne-Ardenne Centre Hospitalier Universitaire de Reims Hôpital Robert-Debré Sorbonne Université Centre Hospitalier Universitaire de Tours

About

Julien Volet is an author at Université de Reims Champagne-Ardenne specializing in oncology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	365
2	Health Sciences	2	2	176
3	Public Health	1	1	17
4	Biostatistics	1	1	12
5	Epidemiology	1	1	17

Julien Volet

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Thierry Conroy, Pascal Hammel, Mohamed Hebbar, New England Journal of Medicine	2018	2.7K
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Thierry Conroy, Pascal Hammel, Mohamed Hebbar, Journal of Clinical Oncology Surgical OncologyLba4001 BackgroundGastroenterologySurgeryPharmacotherapy	2018	138
FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). Laëtitia Dahan, Jean–Marc Phelip, Karine Le Malicot, Journal of Clinical Oncology	2018	53
Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis Capucine Baldini, Anne Escande, Olivier Bouché, Pancreatology Surgical OncologyPancreatic CancerElderly PatientsGastrointestinal OncologyMedicine	2016	39
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials Thomas Aparicio, Michel Ducreux, Roger Faroux, European Journal of Cancer ObesityFfcd TrialsGastrointestinal OncologyMedicineCancer Management	2018	39
Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib Frédérick Moryoussef, Marion Dhooge, Julien Volet, Journal of Cachexia Sarcopenia and Muscle	2015	38
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer Thomas Aparicio, Olivier Bouché, E. François, European Journal of Cancer Geriatric OncologyGeriatricsMedicineCancer ManagementClinical Trials	2018	38
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial Jean‐Baptiste Bachet, Pascal Hammel, Jérôme Desrame, The Lancet. Gastroenterology & hepatology Pancreatic CancerAfugem GercorGastrointestinal OncologyMedicineMetastatic Pancreatic Adenocarcinoma	2017	32
Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience Louis de Mestier, Cindy Neuzillet, Astrid Pozet, European Journal of Surgical Oncology Surgical OncologyGastrointestinal OncologyColorectal SurgeryMedicine4-Year Multicentre Experience	2014	30
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients Cindy Serdjebi, Johan Gagnière, Jérôme Desrame, PLoS ONE	2015	22

Page 1